Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma

  • The PLOS ONE Staff

Correction: Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma

  • The PLOS ONE Staff
PLOS
x

Fig 1, Fig 2, and Fig 4 appear incorrectly in both the HTML and PDF versions of this article. Please view the corrected versions of Fig 1, Fig 2, and Fig 4 here.

thumbnail
Fig 1. Distribution of TP53 codon 72 genotypes among pancreatic ductal adenocarcinoma (PDAC) patients, chronic pancreatic (CP) patients and normal controls.

The p-value was calculated by comparing the Pro/Pro genotype between PDAC patients and normal controls and between CP patients and normal controls.

https://doi.org/10.1371/journal.pone.0126295.g001

thumbnail
Fig 2. Distribution of MDM2 single-nucleotide polymorphism (SNP) 309 genotypes among pancreatic ductal adenocarcinoma (PDAC) patients, chronic pancreatitis (CP) patients and normal controls.

The p-value was calculated by comparing the G/G genotype between PDAC patients and normal controls and between CP patients and normal controls.

https://doi.org/10.1371/journal.pone.0126295.g002

thumbnail
Fig 4. Clinicopathological correlations of TP53 and MDM2 protein expression in pancreatic ductal adenocarcinoma (PDAC) patients, chronic pancreatitis (CP) patients and normal controls.

https://doi.org/10.1371/journal.pone.0126295.g003

Reference

  1. 1. Hori Y, Miyabe K, Yoshida M, Nakazawa T, Hayashi K, Naitoh I, et al. (2015) Impact ofTP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma. PLoS ONE 10(3): e0118829. pmid:25734904